Breaking News

UCB Licenses Ailux Biologics AI Platform

Aims to enable earlier and more widespread use of antibody-antigen structural insights across drug discovery process.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Image: UCB

UCB, a global biopharmaceutical company, and XtalPi, a global AI drug discovery company, entered a license agreement for XtalFold, a biologics AI platform developed by Ailux Biologics, a division of XtalPi. Under the agreement, UCB gains a non-exclusive license to leverage XtalFold for the discovery and engineering of biologics. XtalFold is an AI-based software suite that provides rapid and accurate structural insights to help accelerate biologics discovery across multiple phases. XtalFold...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters